Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Xenon Pharmaceuticals Inc.XENE · Entity 2602 | Chief Financial Officer | September 30, 2026 | October 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Xenon Pharmaceuticals Inc.
Report date September 30, 2026 · Filed October 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 15,000 |
Reported balance
After 2026-09-30 transaction · row 1
1 source rowRow 1 · 2026-09-30 · Purchase · Acquired 15,000 · Balance 15,000 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Deciphera Pharmaceuticals, Inc.
Report date June 11, 2024 · Filed June 11, 2024
Section 16 reporting ended · disclosed 2024-06-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2024-06-11 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2024-06-11 · Grant · Acquired 34,157 · Balance 114,507 F1: Represents restricted stock units ("RSUs") previously granted to the Reporting Person subject to performance-based vesting conditions, for which the performance conditions associated with such RSUs had not yet occurred. Row 2 · 2024-06-11 · Disposition to issuer · Disposed 72,029 · Balance 42,478 F2: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to the Merger Consideration. Row 3 · 2024-06-11 · Other · Disposed 42,478 · Balance 0 F2: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to tax withholding. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.89 | Direct | 0 |
Reported balance
After 2024-06-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-06-11 · Disposition to issuer · Disposed 85,456 · Balance 0 F2: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.95 | Direct | 0 |
Reported balance
After 2024-06-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-06-11 · Disposition to issuer · Disposed 5,650 · Balance 0 F2: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.13 | Direct | 0 |
Reported balance
After 2024-06-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-06-11 · Disposition to issuer · Disposed 103,219 · Balance 0 F2: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.23 | Direct | 0 |
Reported balance
After 2024-06-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-06-11 · Disposition to issuer · Disposed 82,265 · Balance 0 F2: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.27 | Direct | 0 |
Reported balance
After 2024-06-11 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-06-11 · Disposition to issuer · Disposed 82,000 · Balance 0 F2: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.48 | Direct | 0 |
Reported balance
After 2024-06-11 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2024-06-11 · Disposition to issuer · Disposed 65,900 · Balance 0 F2: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.92 | Direct | 0 |
Reported balance
After 2024-06-11 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2024-06-11 · Disposition to issuer · Disposed 69,100 · Balance 0 F2: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") previously granted to the Reporting Person subject to performance-based vesting conditions, for which the performance conditions associated with such RSUs had not yet occurred.
F2: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent.
F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to the Merger Consideration.
F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to tax withholding.
F5: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 07, 2019 Filed Jan 9, 2019 16:54 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Exercise / conversionCommon Stock | 5,000 | $1.89 | $9,450.00 |
DisclosureSEC source: 0001209191-19-003079 · doc4.xml · nonDerivative · entry 1 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 18:53 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | GrantStock Option (Right to Buy) · Derivative | 90,000 | Not disclosed Strike: $29.71 | Not disclosed |
DisclosureSEC source: 0000899243-18-004644 · doc4.xml · derivative · entry 1 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2028-02-16 F1 · price: This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option vests in 48 equal monthly installments following the vesting commencement date of January 1, 2018, subject to continued service through such dates. F1 · derivative.exercise_date: This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option vests in 48 equal monthly installments following the vesting commencement date of January 1, 2018, subject to continued service through such dates. Read SEC document |
| October 02, 2017 Filed Oct 2, 2017 16:33 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Exercise / conversionStock Option (Right to Buy) · Derivative | 103,219 | Not disclosed Strike: $6.13 | Not disclosed |
DisclosureSEC source: 0000899243-17-023128 · doc4.xml · derivative · entry 8 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,219 Underlying: Common Stock · 103,219 shares Expires 2027-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Represents the total number of options to purchase common stock of the Issuer received upon the exchange of options to purchase common stock of Deciphera Pharmaceuticals, Inc. for options to purchase common stock of the Issuer pursuant to the Merger Agreement. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, these options to purchase common stock of Deciphera Pharmaceuticals, LLC were exchanged for options to purchase common stock of the Issuer on a 1 for 5.65 basis pursuant to that certain Reorganization Agreement and Plan of Merger by and among the Issuer, Deciphera Pharmaceuticals, LLC and the other parties named therein, dated September 26, 2017 (the "Merger Agreement"). These transactions were exempt from Section 16(b) in reliance upon Rule 16b-3 and Rule 16b-6(b). F6 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 48 equal monthly installments at the end of each month following the vesting commencement date of May 26, 2017, subject to continued service through Read SEC document |
| October 02, 2017 Filed Oct 2, 2017 16:33 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,269 | Not disclosed Strike: $6.13 | Not disclosed |
DisclosureSEC source: 0000899243-17-023128 · doc4.xml · derivative · entry 7 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 103,219 shares Expires 2027-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Immediately prior to the closing of the Issuer's initial public offering, these options to purchase common stock of Deciphera Pharmaceuticals, LLC were exchanged for options to purchase common stock of the Issuer on a 1 for 5.65 basis pursuant to that certain Reorganization Agreement and Plan of Merger by and among the Issuer, Deciphera Pharmaceuticals, LLC and the other parties named therein, dated September 26, 2017 (the "Merger Agreement"). These transactions were exempt from Section 16(b) in reliance upon Rule 16b-3 and Rule 16b-6(b). F1 · price: Immediately prior to the closing of the Issuer's initial public offering, these options to purchase common stock of Deciphera Pharmaceuticals, LLC were exchanged for options to purchase common stock of the Issuer on a 1 for 5.65 basis pursuant to that certain Reorganization Agreement and Plan of Merger by and among the Issuer, Deciphera Pharmaceuticals, LLC and the other parties named therein, dated September 26, 2017 (the "Merger Agreement"). These transactions were exempt from Section 16(b) in reliance upon Rule 16b-3 and Rule 16b-6(b). F6 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 48 equal monthly installments at the end of each month following the vesting commencement date of May 26, 2017, subject to continued service through Read SEC document |
| October 02, 2017 Filed Oct 2, 2017 16:33 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,650 | Not disclosed Strike: $3.95 | Not disclosed |
DisclosureSEC source: 0000899243-17-023128 · doc4.xml · derivative · entry 6 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,650 Underlying: Common Stock · 5,650 shares Expires 2026-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Represents the total number of options to purchase common stock of the Issuer received upon the exchange of options to purchase common stock of Deciphera Pharmaceuticals, Inc. for options to purchase common stock of the Issuer pursuant to the Merger Agreement. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, these options to purchase common stock of Deciphera Pharmaceuticals, LLC were exchanged for options to purchase common stock of the Issuer on a 1 for 5.65 basis pursuant to that certain Reorganization Agreement and Plan of Merger by and among the Issuer, Deciphera Pharmaceuticals, LLC and the other parties named therein, dated September 26, 2017 (the "Merger Agreement"). These transactions were exempt from Section 16(b) in reliance upon Rule 16b-3 and Rule 16b-6(b). F5 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 48 equal monthly installments at the end of each month following the vesting commencement date of July 1, 2016, subject to continued service through such dates. Read SEC document |
| October 02, 2017 Filed Oct 2, 2017 16:33 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | Not disclosed Strike: $3.95 | Not disclosed |
DisclosureSEC source: 0000899243-17-023128 · doc4.xml · derivative · entry 5 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,650 shares Expires 2026-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Immediately prior to the closing of the Issuer's initial public offering, these options to purchase common stock of Deciphera Pharmaceuticals, LLC were exchanged for options to purchase common stock of the Issuer on a 1 for 5.65 basis pursuant to that certain Reorganization Agreement and Plan of Merger by and among the Issuer, Deciphera Pharmaceuticals, LLC and the other parties named therein, dated September 26, 2017 (the "Merger Agreement"). These transactions were exempt from Section 16(b) in reliance upon Rule 16b-3 and Rule 16b-6(b). F1 · price: Immediately prior to the closing of the Issuer's initial public offering, these options to purchase common stock of Deciphera Pharmaceuticals, LLC were exchanged for options to purchase common stock of the Issuer on a 1 for 5.65 basis pursuant to that certain Reorganization Agreement and Plan of Merger by and among the Issuer, Deciphera Pharmaceuticals, LLC and the other parties named therein, dated September 26, 2017 (the "Merger Agreement"). These transactions were exempt from Section 16(b) in reliance upon Rule 16b-3 and Rule 16b-6(b). F5 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 48 equal monthly installments at the end of each month following the vesting commencement date of July 1, 2016, subject to continued service through such dates. Read SEC document |
| October 02, 2017 Filed Oct 2, 2017 16:33 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Exercise / conversionStock Option (Right to Buy) · Derivative | 38,448 | Not disclosed Strike: $1.89 | Not disclosed |
DisclosureSEC source: 0000899243-17-023128 · doc4.xml · derivative · entry 4 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,448 Underlying: Common Stock · 38,448 shares Expires 2025-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Represents the total number of options to purchase common stock of the Issuer received upon the exchange of options to purchase common stock of Deciphera Pharmaceuticals, Inc. for options to purchase common stock of the Issuer pursuant to the Merger Agreement. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, these options to purchase common stock of Deciphera Pharmaceuticals, LLC were exchanged for options to purchase common stock of the Issuer on a 1 for 5.65 basis pursuant to that certain Reorganization Agreement and Plan of Merger by and among the Issuer, Deciphera Pharmaceuticals, LLC and the other parties named therein, dated September 26, 2017 (the "Merger Agreement"). These transactions were exempt from Section 16(b) in reliance upon Rule 16b-3 and Rule 16b-6(b). F4 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 48 equal monthly installments at the end of each month following the vesting commencement date of September 30, 2015, subject to continued service through such dates. Read SEC document |
| October 02, 2017 Filed Oct 2, 2017 16:33 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,805 | Not disclosed Strike: $1.89 | Not disclosed |
DisclosureSEC source: 0000899243-17-023128 · doc4.xml · derivative · entry 3 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 38,448 shares Expires 2025-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Immediately prior to the closing of the Issuer's initial public offering, these options to purchase common stock of Deciphera Pharmaceuticals, LLC were exchanged for options to purchase common stock of the Issuer on a 1 for 5.65 basis pursuant to that certain Reorganization Agreement and Plan of Merger by and among the Issuer, Deciphera Pharmaceuticals, LLC and the other parties named therein, dated September 26, 2017 (the "Merger Agreement"). These transactions were exempt from Section 16(b) in reliance upon Rule 16b-3 and Rule 16b-6(b). F1 · price: Immediately prior to the closing of the Issuer's initial public offering, these options to purchase common stock of Deciphera Pharmaceuticals, LLC were exchanged for options to purchase common stock of the Issuer on a 1 for 5.65 basis pursuant to that certain Reorganization Agreement and Plan of Merger by and among the Issuer, Deciphera Pharmaceuticals, LLC and the other parties named therein, dated September 26, 2017 (the "Merger Agreement"). These transactions were exempt from Section 16(b) in reliance upon Rule 16b-3 and Rule 16b-6(b). F4 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 48 equal monthly installments at the end of each month following the vesting commencement date of September 30, 2015, subject to continued service through such dates. Read SEC document |
| October 02, 2017 Filed Oct 2, 2017 16:33 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Exercise / conversionStock Option (Right to Buy) · Derivative | 173,008 | Not disclosed Strike: $1.89 | Not disclosed |
DisclosureSEC source: 0000899243-17-023128 · doc4.xml · derivative · entry 2 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,008 Underlying: Common Stock · 173,008 shares Expires 2025-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Represents the total number of options to purchase common stock of the Issuer received upon the exchange of options to purchase common stock of Deciphera Pharmaceuticals, Inc. for options to purchase common stock of the Issuer pursuant to the Merger Agreement. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, these options to purchase common stock of Deciphera Pharmaceuticals, LLC were exchanged for options to purchase common stock of the Issuer on a 1 for 5.65 basis pursuant to that certain Reorganization Agreement and Plan of Merger by and among the Issuer, Deciphera Pharmaceuticals, LLC and the other parties named therein, dated September 26, 2017 (the "Merger Agreement"). These transactions were exempt from Section 16(b) in reliance upon Rule 16b-3 and Rule 16b-6(b). F2 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 16 equal quarterly installments at the end of each quarter following the vesting commencement date of February 23, 2015, subject to continued service through such dates. Read SEC document |
| October 02, 2017 Filed Oct 2, 2017 16:33 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,621 | Not disclosed Strike: $1.89 | Not disclosed |
DisclosureSEC source: 0000899243-17-023128 · doc4.xml · derivative · entry 1 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 173,008 shares Expires 2025-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Immediately prior to the closing of the Issuer's initial public offering, these options to purchase common stock of Deciphera Pharmaceuticals, LLC were exchanged for options to purchase common stock of the Issuer on a 1 for 5.65 basis pursuant to that certain Reorganization Agreement and Plan of Merger by and among the Issuer, Deciphera Pharmaceuticals, LLC and the other parties named therein, dated September 26, 2017 (the "Merger Agreement"). These transactions were exempt from Section 16(b) in reliance upon Rule 16b-3 and Rule 16b-6(b). F1 · price: Immediately prior to the closing of the Issuer's initial public offering, these options to purchase common stock of Deciphera Pharmaceuticals, LLC were exchanged for options to purchase common stock of the Issuer on a 1 for 5.65 basis pursuant to that certain Reorganization Agreement and Plan of Merger by and among the Issuer, Deciphera Pharmaceuticals, LLC and the other parties named therein, dated September 26, 2017 (the "Merger Agreement"). These transactions were exempt from Section 16(b) in reliance upon Rule 16b-3 and Rule 16b-6(b). F2 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 16 equal quarterly installments at the end of each quarter following the vesting commencement date of February 23, 2015, subject to continued service through such dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.